Good morning, Plenty of deal news to bring you from across MedTech and biotech. My summary covers headlines from gene editing, respiratory diagnostics, neuroscience, and more.
🔔 Scribe Therapeutics has overshot its own expectations with an IPO that’s set to bring in $128.7 million for the in vivo gene editing outfit.
🔔Tempus buys out cancer genomics partner Personalis in $1.5 billion deal
🔔Cambridge-based health tech startup TidalSense has raised £14.2m in a funding round to accelerate the commercial expansion of its AI-powered respiratory diagnostic device.
🔔Crystalys Therapeutics has raised $130 million in series B financing to advance the development of its gout drug dotinurad and prepare for a potential commercial launch.
🔔Jupiter Neurosciences will pay $3.3 million upfront to Canada’s PharmAla Biotech for the U.S. rights to an MDMA drug to treat neuropsychiatric disorders.
🔔RapidPulse has raised $48 million in an oversubscribed Series B financing to advance the clinical development of its aspiration technology for treating acute ischemic stroke.
🔔Swiss biotech Neurimmune has sold part of its future royalties from its AstraZeneca-partnered experimental heart drug cliramitug to Royalty Pharma for up to $425m
🔔argenx has agreed to acquire Forte Biosciences for €1.9 bn, gaining FB102, an early-stage antibody that has already produced efficacy signals in vitiligo and celiac disease.
🔔Newly formed Synaptiq Therapeutics has acquired substantially all the assets of Nobias Therapeutis.
🔔Belgian techbio Sightera Biosciences has raised €3 million in pre-seed financing to expand its AI drug discovery platform and advance a pipeline of small molecules in oncology and fibrosis.
🔔Wellumio, a Wellington-based medical device company developing a portable brain imaging device for stroke detection, said on July 24 it had reached the final close of an oversubscribed $9.75 million pre-series A round.
🔔MedTech startup Bioscan Research which is leveraging deeptech in optics, electronics, mechanics and software to develop, test, manufacture and commercialize affordable medical devices for early detection of brain injuries non-invasively, has raised $1m
===============
Newton Colmore is a specialist search firm and we connect exceptional engineering and scientific talent with impactful companies, globally.